GO:0040037 negative regulation of fibroblast growth factor receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0040037 describes any process that stops, prevents, or reduces the frequency, rate or extent of fibroblast growth factor receptor (FGFR) signaling pathway activity.
• Negative regulation of FGFR signaling is achieved by multiple mechanisms, including receptor internalization and degradation, dephosphorylation by phosphatases, and inhibition by intracellular binding proteins.
• Dysregulated negative regulation of FGFR signaling contributes to cancer, developmental disorders, and metabolic diseases [1,6,8].
• Key negative regulators include SPRY proteins, MKP3 (DUSP6), SEF, and CBL, which act at different nodes of the FGFR pathway.
• Experimental approaches to study this process include CRISPR knockout of negative regulators, phospho-proteomics, and live-cell imaging of FGFR trafficking [1,3].
• Understanding negative regulation of FGFR signaling is critical for developing targeted therapies, as FGFR inhibitors are used in cancers with aberrant FGFR activity [3,8].
Description
Fibroblast growth factor receptor (FGFR) signaling controls fundamental cellular processes such as proliferation, differentiation, migration, and survival. To prevent excessive or inappropriate signaling, cells have evolved intricate negative regulatory mechanisms that collectively constitute the Gene Ontology term GO:0040037, negative regulation of fibroblast growth factor receptor signaling pathway. This process is essential for normal development and tissue homeostasis, and its disruption is implicated in a wide range of pathologies, including cancer, skeletal disorders, and metabolic diseases [1,6,8]. Researchers studying FGFR signaling need to understand these negative regulatory mechanisms to interpret experimental data and to identify therapeutic targets. This article provides a comprehensive overview of GO:0040037, covering its definition, molecular mechanisms, key genes, disease relevance, and research methods, based on authoritative QuickGO data and published literature [1-8].
negative regulation of fibroblast growth factor receptor signaling pathway At A Glance
| GO ID | GO:0040037 |
|---|---|
| GO term | negative regulation of fibroblast growth factor receptor signaling pathway |
| Ontology | biological_process |
| Synonym | inhibition of fibroblast growth factor receptor signaling pathway; negative regulation of FGF receptor signaling pathway; downregulation of fibroblast growth factor receptor signaling pathway |
| Major function | Attenuation or termination of FGFR-mediated signal transduction |
| Key regulators | SPRY, DUSP6 (MKP3), SEF, CBL, PP2A, and others |
| Disease relevance | Cancer, developmental syndromes, metabolic disorders [1,6,8] |
| Research methods | CRISPR knockout, phospho-proteomics, live-cell imaging, biochemical assays [1,3] |
What Is GO:0040037?
GO:0040037, negative regulation of fibroblast growth factor receptor signaling pathway, is defined as any process that stops, prevents, or reduces the frequency, rate or extent of fibroblast growth factor receptor signaling pathway activity. In other words, it encompasses all molecular events that attenuate or terminate signals initiated by FGFR activation, ensuring balanced cellular responses.
Why Is negative regulation of fibroblast growth factor receptor signaling pathway Important in Cell Biology?
Negative regulation of FGFR signaling is crucial for preventing uncontrolled cell growth and maintaining tissue homeostasis. Aberrant FGFR signaling due to loss of negative regulators is a hallmark of many cancers, making this process a key area of research for understanding tumorigenesis and for developing targeted therapies [1,6].
• Prevents excessive FGFR signaling that could lead to cancer [1,6].
• Essential for normal embryonic development and organogenesis.
• Regulates cell proliferation, differentiation, and migration.
• Dysregulation is linked to skeletal disorders such as craniosynostosis.
• Involved in metabolic diseases, including cholestatic liver disease.
• Provides targets for therapeutic intervention in FGFR-driven cancers.
• Modulates tumor microenvironment and immune cell infiltration.
• Affects cholesterol storage and tumor cell invasion.
• Plays a role in wound healing and fibroblast activation.
• Contributes to autophagy regulation and metabolic dysfunction.
What Happens During negative regulation of fibroblast growth factor receptor signaling pathway?
Receptor Internalization and Degradation
In simple terms: After FGFR is activated, it is pulled inside the cell and broken down to stop the signal.
Upon ligand binding, FGFRs are activated and subsequently internalized through clathrin-mediated endocytosis. The E3 ubiquitin ligase CBL ubiquitinates activated FGFRs, targeting them for degradation in lysosomes, thereby terminating signaling. This process is a major mechanism of negative regulation.
Dephosphorylation by Phosphatases
In simple terms: Enzymes called phosphatases remove phosphate groups from FGFR, turning off the signal.
Protein phosphatases, such as PP2A and MKP3 (DUSP6), dephosphorylate key tyrosine residues on FGFR or its downstream effectors like ERK, thereby attenuating the signaling cascade. This reversible modification provides a rapid way to shut down the pathway.
Inhibition by Intracellular Binding Proteins
In simple terms: Special proteins bind to FGFR or its partners and block the signal from being transmitted.
Proteins like SPRY (Sprouty) and SEF (similar expression to FGF) are induced by FGFR signaling and act as feedback inhibitors. SPRY proteins interfere with the Ras-MAPK pathway, while SEF binds to FGFR and inhibits its activity, forming negative feedback loops.
Regulation by Autophagy
In simple terms: The cell's recycling system can also degrade FGFR or its regulators to control signaling.
Recent studies have shown that autophagic degradation of SQSTM1/p62 affects fibroblast activation and wound healing, indirectly influencing FGFR signaling. Additionally, protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via mTORC1, which may intersect with FGFR signaling.
Key Genes Involved in GO:0040037 negative regulation of fibroblast growth factor receptor signaling pathway
The following genes and proteins are key players in the negative regulation of FGFR signaling, as supported by published literature [1-8].
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPRY1 | Inhibits Ras-MAPK pathway downstream of FGFR | Feedback inhibitor; knockout leads to enhanced FGFR signaling |
| SPRY2 | Antagonizes FGFR signaling by interfering with GRB2-SOS complex | Frequently downregulated in cancers |
| SPRY4 | Modulates FGFR signaling in development | Associated with skeletal disorders |
| DUSP6 (MKP3) | Dephosphorylates ERK, attenuating FGFR-induced MAPK signaling | Negative feedback regulator; loss causes hyperactivation |
| SEF (IL17RD) | Binds to FGFR and inhibits its activity | Involved in developmental processes |
| CBL | E3 ubiquitin ligase that targets FGFR for degradation | Regulates receptor turnover |
| PP2A | Dephosphorylates FGFR and downstream effectors | Tumor suppressor role |
| SQSTM1 (p62) | Autophagic degradation of signaling components | Affects fibroblast activation and wound healing |
| PPP6C | Protein phosphatase 6 catalytic subunit | Regulates mTORC1 and metabolic dysfunction |
| FGFR1 | Receptor tyrosine kinase; subject to negative regulation | Amplified in breast cancer and others |
| FGFR2 | Receptor tyrosine kinase; subject to negative regulation | Mutations in craniosynostosis |
| FGFR3 | Receptor tyrosine kinase; subject to negative regulation | Mutations in skeletal dysplasia |
| FGFR4 | Receptor tyrosine kinase; subject to negative regulation | Target in cholestatic liver disease |
| FGF19 | Ligand for FGFR4; signaling is negatively regulated | Involved in bile acid metabolism |
| SOAT1 | Cholesterol esterification enzyme; modulated by FGFR signaling | Promotes mammary tumor invasion |
| SPRED | Inhibits Ras-MAPK pathway | Negative regulator of FGFR signaling |
| PTPN11 (SHP2) | Phosphatase that can both promote and inhibit FGFR signaling | Mutations in Noonan syndrome |
| GRB2 | Adaptor protein; its interaction with SPRY affects signaling | Target for disrupting negative regulation |
How Is negative regulation of fibroblast growth factor receptor signaling pathway Regulated?
The negative regulation of FGFR signaling is itself tightly controlled. For example, SPRY and SEF are transcriptional targets of FGFR signaling, creating negative feedback loops. Additionally, the mTORC1 pathway can influence FGFR signaling through metabolic cues, as shown by protein phosphatase 6 regulation of mTORC1 in steatohepatitis. Autophagic processes also modulate the availability of signaling components.
negative regulation of fibroblast growth factor receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGFR1 | Breast cancer, bladder cancer | Knockout of SPRY1 in cancer cell lines [1,3] |
| FGFR2 | Craniosynostosis, cancer | Point mutation knock-in in mice |
| FGFR3 | Skeletal dysplasia, bladder cancer | Overexpression of DUSP6 in cell models [1,6] |
| FGFR4 | Cholestatic liver disease | Knockout of FGF19 in mice |
| SQSTM1 | Wound healing, fibrosis | Autophagy-deficient models |
Cancer
Loss of negative regulators of FGFR signaling leads to constitutive pathway activation, driving tumorigenesis in breast, bladder, and other cancers [1,6]. For instance, FGFR blockade in triple-negative breast cancer boosts T cell infiltration by regulating cancer-associated fibroblasts. Furthermore, FGFR signaling modulates cholesterol storage via SOAT1 to promote mammary tumor cell invasion.
Developmental Disorders
Mutations in FGFRs or their negative regulators cause skeletal syndromes such as craniosynostosis and dwarfism. Proper negative regulation is essential for normal bone development.
Metabolic and Liver Diseases
The FGF19-FGFR4 pathway is implicated in cholestatic and metabolic diseases, and its negative regulation is critical for bile acid homeostasis. Protein phosphatase 6, a negative regulator, is linked to metabolic dysfunction-associated steatohepatitis.
Wound Healing and Fibrosis
Autophagic degradation of SQSTM1 enables fibroblast activation to accelerate wound healing, highlighting the role of negative regulation in tissue repair.
From negative regulation of fibroblast growth factor receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Effect of SPRY1 loss on FGFR signaling | CRISPR knockout of SPRY1 in HEK293 or cancer cells |
| Role of DUSP6 in ERK dephosphorylation | Point mutation of catalytic cysteine in DUSP6 |
| Impact of CBL-mediated degradation on FGFR levels | Knock-in of ubiquitin-deficient FGFR mutant |
| Consequence of SEF overexpression | Overexpression of SEF in zebrafish or cell lines |
| Autophagy's role in FGFR regulation | Knockout of SQSTM1 in fibroblasts |
| Metabolic regulation by PP6 | Knockout of PPP6C in hepatocytes |
How to Study the negative regulation of fibroblast growth factor receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on FGFR signaling | Identify negative regulators |
| Phospho-proteomics | Changes in phosphorylation | Quantify pathway activity |
| Live-cell imaging | Receptor trafficking and degradation | Visualize internalization |
| Co-immunoprecipitation | Protein-protein interactions | Detect binding of regulators |
| Ubiquitination assay | Post-translational modification | Assess CBL-mediated degradation |
| Luciferase reporter | Transcriptional output of FGFR signaling | Measure pathway activity |
| RNA-seq | Gene expression changes | Identify feedback regulators |
| Autophagy flux assay | Autophagic degradation | Study SQSTM1 role |
CRISPR Knockout Screens
Genome-wide CRISPR knockout screens can identify negative regulators of FGFR signaling by selecting for cells with enhanced pathway activity. This approach has uncovered novel components such as SPRY and DUSP6.
Phospho-Proteomics
Mass spectrometry-based phospho-proteomics allows quantification of phosphorylation changes on FGFR and downstream effectors upon negative regulator perturbation. This reveals dynamic signaling events.
Live-Cell Imaging
Fluorescently tagged FGFR and regulators can be imaged in live cells to track internalization, trafficking, and degradation in real time. This provides spatiotemporal insights.
Biochemical Assays
Co-immunoprecipitation, ubiquitination assays, and phosphatase activity assays are used to dissect molecular interactions and enzymatic functions of negative regulators.
How CRISPR Can Be Used to Study GO:0040037 negative regulation of fibroblast growth factor receptor signaling pathway
Knockout
CRISPR knockout of negative regulators such as SPRY1, DUSP6, or CBL leads to enhanced FGFR signaling, providing causal evidence for their roles. These models are valuable for studying pathway hyperactivation in cancer.
Point Mutation
Introducing point mutations in catalytic residues of phosphatases (e.g., DUSP6) or ubiquitin-acceptor sites in FGFR can dissect specific mechanisms of negative regulation. Such models help distinguish between scaffolding and enzymatic functions.
Knock-in
Knock-in of tagged versions of FGFR or regulators (e.g., GFP-FGFR) allows real-time imaging and biochemical tracking of the receptor. This is useful for studying trafficking and degradation dynamics.
Overexpression
Overexpression of negative regulators like SPRY or SEF can suppress FGFR signaling, offering a way to test their inhibitory capacity. This approach is also used to rescue phenotypes caused by their loss.
How EDITGENE Supports negative regulation of fibroblast growth factor receptor signaling pathway Research
Researchers studying negative regulation of fibroblast growth factor receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in attenuating FGFR signaling, and to dissect the precise molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations with high efficiency and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of fibroblast growth factor receptor signaling pathway research.
Frequently Asked Questions About negative regulation of fibroblast growth factor receptor signaling pathway
What is GO:0040037?
GO:0040037 is the Gene Ontology term for negative regulation of fibroblast growth factor receptor signaling pathway, describing any process that stops, prevents, or reduces FGFR signaling activity.
What genes are involved in negative regulation of FGFR signaling?
Key genes include SPRY1-4, DUSP6 (MKP3), SEF (IL17RD), CBL, PP2A, and SQSTM1, among others [1,4].
How does negative regulation of FGFR signaling occur?
It occurs through receptor internalization and degradation, dephosphorylation by phosphatases, inhibition by binding proteins like SPRY and SEF, and autophagy [1,4].
Why is negative regulation of FGFR signaling important in cancer?
Loss of negative regulation leads to constitutive FGFR activation, driving tumor growth and progression in many cancers [1,6].
What diseases are associated with defective negative regulation of FGFR signaling?
Diseases include breast cancer, bladder cancer, craniosynostosis, cholestatic liver disease, and metabolic dysfunction-associated steatohepatitis [1,3,6,8].
What experimental models are used to study negative regulation of FGFR signaling?
Common models include CRISPR knockout cell lines, point mutation knock-ins, overexpression systems, and animal models.
How can CRISPR be used to study negative regulation of FGFR signaling?
CRISPR can knockout negative regulators to observe enhanced signaling, introduce point mutations to dissect mechanisms, or knock-in tags for imaging.
What is the role of DUSP6 in FGFR signaling?
DUSP6 (MKP3) dephosphorylates ERK, thereby attenuating FGFR-induced MAPK signaling as a negative feedback regulator.
How does SPRY inhibit FGFR signaling?
SPRY proteins interfere with the Ras-MAPK pathway downstream of FGFR, acting as feedback inhibitors.
What services does EDITGENE offer for studying negative regulation of FGFR signaling?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression models, library screening, and bioinformatics services.
Conclusion
Negative regulation of fibroblast growth factor receptor signaling pathway (GO:0040037) is a critical process that ensures balanced FGFR signaling, with profound implications for development and disease. Understanding its mechanisms, key regulators, and disease connections provides a foundation for therapeutic targeting. EDITGENE's CRISPR services empower researchers to dissect this pathway with precision and scale.
References
- 1. Szybowska P et al.. 2021. Negative Regulation of FGFR (Fibroblast Growth Factor Receptor) Signaling.. Cells 10(6) PMID: 34071546
- 2. Liu Z et al.. 2025. Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway.. J Hepatol 83(3):630-642 PMID: 39947331
- 3. Wu Y et al.. 2022. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts.. Theranostics 12(10):4564-4580 PMID: 35832090
- 4. Xu Y et al.. 2025. Autophagic degradation of SQSTM1 enables fibroblast activation to accelerate wound healing.. Autophagy 21(11):2401-2421 PMID: 40400126
- 6. Chaffer CL et al.. 2007. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers.. Differentiation 75(9):831-42 PMID: 17697126
- 7. Tuokkola JE et al.. 2025. Fibroblast growth factor receptor signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor cell invasion.. Breast Cancer Res 27(1):132 PMID: 40665359
- 8. Li X et al.. 2024. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.. J Intern Med 295(3):292-312 PMID: 38212977
